Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4
Authors:
- 6 September 2022
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 372, 577966
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapyMultiple Sclerosis Journal, 2018
- Cladribine treatment of multiple sclerosis is associated with depletion of memory B cellsJournal of Neurology, 2018
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyMultiple Sclerosis Journal, 2017
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Multiple Sclerosis and Related Disorders, 2015
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThe Lancet Neurology, 2014
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisThe Lancet Neurology, 2011
- Impact of cladribine on soluble adhesion molecules in multiple sclerosisActa Neurologica Scandinavica, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Cladribine impedesin vitromigration of mononuclear cells: a possible implication for treating multiple sclerosisEuropean Journal of Neurology, 2009
- Rating neurologic impairment in multiple sclerosisNeurology, 1983